spacer
home > ebr > winter 2002 > patent protection for genes and other parts of the human body under ec law
PUBLICATIONS
European Biopharmaceutical Review

Patent Protection for Genes and Other Parts of the Human Body under EC Law

After a decade of heated controversies, in 1998 the Council of the European Union and the European Parliament finally adopted the European Community's Directive 98/44/EC on the Legal Protection of Biotechnological Inventions (1). The EC Biotechnology Directive was hailed as a breakthrough in favour of the necessary incentives for research and development, especially in the area of diagnostic and therapeutic tools as well as new pharmaceuticals (2). However, recent controversies have rekindled the legal battle over patents on genes and DNA sequences. In particular, the patent on the BRCA gene (3) (related to breast cancer) raises highly plausible concerns about exclusive rights over the gene's diagnostic functions and the use of all proteins coded for by the patented DNA sequence. Within the scientific community, the call for a cautious approach to patents on DNA sequences has gathered considerable force (4).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Professor Matthias Herdegen, Director of the Institute of International Law and the Institute for Public Law, University of Bonn Professor Matthias Herdegen is Director of the Institute of International Law and the Institute for Public Law at the University of Bonn.
He is the editor and author of a loose-leaf collection on international biotechnology law, which includes the legislation of the EU, European countries, the US, Japan, China and other countries and international treaties, as well as commentaries on these legal instruments.

spacer
Professor Matthias Herdegen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement